These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9363156)

  • 1. Low molecular weight heparin for the prevention of deep vein thrombosis following orthopedic surgery.
    Lassen MR; Borris LC
    Curr Opin Pulm Med; 1996 Jul; 2(4):300-4. PubMed ID: 9363156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparin for the prevention and treatment of venous thromboembolism.
    Raskob GE
    Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
    Whang PG; Lieberman JR
    Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep vein thrombosis prophylaxis in the outpatient setting: preventing complications following hospital discharge.
    Turpie AG
    Orthopedics; 1995 Jul; 18 Suppl():15-7. PubMed ID: 7479420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of low molecular weight heparin in total knee arthroplasty.
    Iobst CA; Friedman RJ
    Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thrombosis prophylaxis in orthopaedic surgery: considerations and uncertainties].
    Ettema HB; Hoppener MR; Büller HR; Henny ChP; Verheyen CC
    Ned Tijdschr Geneeskd; 2003 Sep; 147(38):1842-7. PubMed ID: 14533495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prophylaxis for deep vein thrombosis with low molecular weight heparin following hip and knee surgery].
    Li XL; Lu WJ; Yu NS
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2001 Jan; 15(1):39-41. PubMed ID: 12563929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
    Abad JI; Gómez-Outes A; Martínez-González J; Rocha E;
    Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Low-molecular-weight heparin for preventing deep-vein thrombosis after total joint arthroplasty].
    Yang G; Lu H; Gao J; Kou B; Yuan Y; Xu B
    Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):25-7. PubMed ID: 11831980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital: a 10-year prospective register of 3,954 patients.
    Dahl OE; Gudmundsen TE; Bjørnarå BT; Solheim DM
    Acta Orthop Scand; 2003 Jun; 74(3):299-304. PubMed ID: 12899550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ''critical thrombosis period'' in major orthopedic surgery: when to start and when to stop prophylaxis.
    Warwick D; Rosencher N
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):394-405. PubMed ID: 20019020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Initial clinical experiences with low molecular weight heparin in the prevention of thrombosis in orthopedic surgery].
    Schwarz B; Mittelmeier H
    Aktuelle Traumatol; 1988 Oct; 18(5):226-32. PubMed ID: 2907248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.